Companies › Dendreon
1 active drug program in 5 registered trials: 3 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2031.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sipuleucel-T Prostatic acid phosphatase binding agent | ACP3 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC); Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Metastatic Castration-Resistant Prostate Adenocarcinoma | Dec 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05751941 | Sipuleucel-T | Phase 2 | Prostate Cancer | Oncology | Dec 2026 |
| NCT06100705 | Sipuleucel-T | Phase 2 | Metastatic Castration-resistant Prostate Cancer | Oncology | Dec 2027 |
| NCT05806814 | Sipuleucel-T | Phase 1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Oncology | May 2028 |
| NCT07219147 | Sipuleucel-T | Phase 1 | Metastatic Castration-Resistant Prostate Adenocarcinoma | Oncology | Jul 2028 |
| NCT06134232 | Sipuleucel-T | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Oncology | Dec 2031 |
–
CNBG-Virogin Biotech (Shanghai) Stella Pharma Hangzhou Converd Abscint NV/SA Beijing Gene Key Life Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.